Development of vaccines against Crimean-Congo haemorrhagic fever virus

Vaccine

Volumn 35, Issue 44, 2017, Pages 6015-6023

  Dowall, Stuart D ^a   Carroll, Miles W ^a   Hewson, Roger ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Crimean Congo haemorrhagic fever; Review; Vaccine

Indexed keywords

ADENOVIRUS VACCINE; DNA VACCINE; INACTIVATED VACCINE; RIBAVIRIN; SUBUNIT VACCINE; VIRUS VACCINE; VIRUS VECTOR; VACCINE;

ARTHROPOD LIFE CYCLE STAGE; ARTICLE; CRIMEAN CONGO HEMORRHAGIC FEVER; CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS; DISEASE MODEL; GEOGRAPHY; HUMAN; HYALOMMA; IMMUNOGENICITY; LIVESTOCK; MIGRANT BIRD; MORTALITY RATE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; UNITED KINGDOM; VIREMIA; VIRUS TRANSMISSION; ANIMAL; CROSS INFECTION; IMMUNOLOGY; INCIDENCE; IXODIDAE; PROCEDURES;

ANIMALS; CROSS INFECTION; GEOGRAPHY; HEMORRHAGIC FEVER VIRUS, CRIMEAN-CONGO; HEMORRHAGIC FEVER, CRIMEAN; HUMANS; INCIDENCE; IXODIDAE; VACCINES;

EID: 85021746076     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.05.031     Document Type: Article

References (127)

1. Leblebicioglu, H., Crimean-Congo haemorrhagic fever in Eurasia. Int J of Antimicrobial Agents 36:Suppl 1 (2010), S43–S46.
2. Vorou, R., Pierroutsakos, I.N., Maltezou, H.C., Crimean-Congo hemorrhagic fever. Curr Opin Infect Dis 20 (2007), 495–500.
3. Whitehouse, C.A., Crimean-Congo hemorrhagic fever. Antiv Res 64 (2004), 145–160.
4. Chumakov, M.P., A new tick-borne virus disease-Crimean hemorrhagic fever (acute infectious capillary toxicosis). Sokolov, A.E., Chumakov, M.P., Kolachev, A.A., (eds.) Crimean hemorrhagic fever (acute infectious capillary toxicosis). Izdanie Otdel'noj Primorskoj Armii, Simferopol, USSR, 1945 [Russian].
5. Chumakov, M.P., A short review of the investigation of the virus of Crimean hemorrhagic fever. Chumakov, M.P., (eds.) Endemic viral infections: sborn trud inst polio virus encefal, akad med nauk USSR [Russian; NAMRU-3 translation T189], 1965, 193–196.
6. Chumakov, M.P., On 30 years of investigation of Crimean hemorrhagic fever. Trudi Inst Polio Virusn Entsefalitov Akad Med Nauk, USSR 22 (1974), 5–18 [Russian; NAMRU-3 translation T950].
7. Simpson, D.I., Knight, E.M., Courtois, G., Williams, M.C., Weinbren, M.P., Kibukamusoke, J.W., Congo virus: a hitherto undescribed virus occurring in Africa. I. Human isolations–clinical notes. East Afr Med J 44 (1967), 86–92.
8. Woodall, J.P., Personal Reflections. Ergonul, O., Whitehouse, C.A., (eds.) Crimean-congo hemorrhagic fever: a global perspective, 2007, Springer, 23–32.
9. Estrada-Pena, A., Venzal, J.M., Climate niches of tick species in the Mediterranean region: modeling of occurrence data, distributional constraints, and impact of climate change. J Med Entomol 44 (2007), 1130–1138.
10. Randolph, S.E., Rogers, D.J., The arrival, establishment and spread of exotic diseases: patterns and predictions. Nat Rev Microbiol 8 (2010), 361–371.
11. Bente, D.A., Forrester, N.L., Watts, D.M., McAuley, A.J., Whitehouse, C.A., Bray, M., Crimean-Congo hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antivir Res 100 (2013), 159–189.
12. Aradaib, I.E., Erickson, B.R., Mustafa, M.E., Khristova, M.L., Saeed, N.S., Elageb, R.M., et al. Nosocomial outbreak of Crimean-Congo hemorrhagic fever, Sudan. Emerg Inf Dis 16 (2010), 837–839.
13. Ergonul, O., Crimean-Congo hemorrhagic fever virus: new outbreaks, new discoveries. Curr Opin Virol 2 (2012), 215–220.
14. Mardani, M., Keshtkar-Jahromi, M., Ataie, B., Adibi, P., Crimean-Congo hemorrhagic fever virus as a nosocomial pathogen in Iran. The Am J Trop Med Hyg 81 (2009), 675–678.
15. Mourya, D.T., Yadav, P.D., Shete, A.M., Gurav, Y.K., Raut, C.G., Jadi, R.S., et al. Detection, isolation and confirmation of Crimean-Congo hemorrhagic fever virus in human, ticks and animals in Ahmadabad, India, 2010–2011. PLoS Negl Trop Dis, 6, 2012, e1653.
16. Hasan, Z., Mahmood, F., Jamil, B., Atkinson, B., Mohammed, M., Samreen, A., et al. Crimean-Congo hemorrhagic fever nosocomial infection in a immunosuppressed patient, Pakistan: case report and virological investigation. J Med Virol 85 (2013), 501–504.
17. Athar, M.N., Khalid, M.A., Ahmad, A.M., Bashir, N., Baqai, H.Z., Ahmad, M., et al. Crimean-Congo hemorrhagic fever outbreak in Rawalpindi, Pakistan, February 2002: contact tracing and risk assessment. The Am J Trop Med Hyg 72 (2005), 471–473.
18. Maltezou, H.C., Papa, A., Crimean-Congo hemorrhagic fever: risk for emergence of new endemic foci in Europe?. Travel Med Infect Dis 8 (2010), 139–143.
19. Jamil, B., Hasan, R.S., Sarwari, A.R., Burton, J., Hewson, R., Clegg, C., Crimean-Congo hemorrhagic fever: experience at a tertiary care hospital in Karachi, Pakistan. Trans R Soc Trop Med Hyg 99 (2005), 577–584.
20. Rehman, A., Baloch, N.U., Awais, M., Eid-ul-Azha festival in Pakistan: a vulnerable time for Crimean-Congo hemorrhagic fever outbreak. Am J Inf Control 42 (2014), 939–940.
21. Mallhi, T.H., Khan, Y.H., Sarriff, A., Khan, A.H., Crimean-Congo haemorrhagic fever virus and Eid-Ul-Adha festival in Pakistan. The Lancet Infect Dis 16 (2016), 1332–1333.
22. Leblebicioglu, H., Sunbul, M., Memish, Z.A., Al-Tawfiq, J.A., Bodur, H., Ozkul, A., et al. Consensus report: preventive measures for Crimean-Congo Hemorrhagic Fever during Eid-al-Adha festival. Int J Infect Dis: IJID: Off Publ Int Soc Infect Dis 38 (2015), 9–15.
23. Mertens, M., Schmidt, K., Ozkul, A., Groschup, M.H., The impact of Crimean-Congo hemorrhagic fever virus on public health. Antivir Res 98 (2013), 248–260.
24. Sidwell, R.W., Smee, D.F., Viruses of the Bunya- and Togaviridae families: potential as bioterrorism agents and means of control. Antivir Res 57 (2003), 101–111.
25. Zilinskas, R.A., Iraq's biological weapons. The past as future?. Jama. 278 (1997), 418–424.
26. Bronze, M.S., Huycke, M.M., Machado, L.J., Voskuhl, G.W., Greenfield, R.A., Viral agents as biological weapons and agents of bioterrorism. The Am J Medi Sci 323 (2002), 316–325.
27. Burt, F.J., Swanepoel, R., Shieh, W.J., Smith, J.F., Leman, P.A., Greer, P.W., et al. Immunohistochemical and in situ localization of Crimean-Congo hemorrhagic fever (CCHF) virus in human tissues and implications for CCHF pathogenesis. Arch Pathol Lab Med 121 (1997), 839–846.
28. Swanepoel, R., Gill, D.E., Shepherd, A.J., Leman, P.A., Mynhardt, J.H., Harvey, S., The clinical pathology of Crimean-Congo hemorrhagic fever. Rev Infect Dis 11:Suppl 4 (1989), S794–S800.
29. Bray, M.D., Comparative Pathogenesis of Crimean Congo Hemorrhagic Fever and Ebola Hemorrhagic Fever. Ergonul, O., Whitehouse, C.A., (eds.) Crimean-Congo hemorrhagic fever: a global perspective, 2007, Springer, 221–231.
30. Baseler, L., Chertow, D.S., Johnson, K.M., Feldmann, H., Morens, D.M., The pathogenesis of ebola virus disease. Ann Rev Pathol 12 (2017), 387–418.
31. Ergonul, O., Tuncbilek, S., Baykam, N., Celikbas, A., Dokuzoguz, B., Evaluation of serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha in patients with Crimean-Congo hemorrhagic fever. The J Infect Dis 193 (2006), 941–944.
32. Saksida, A., Duh, D., Wraber, B., Dedushaj, I., Ahmeti, S., Avsic-Zupanc, T., Interacting roles of immune mechanisms and viral load in the pathogenesis of crimean-congo hemorrhagic fever. Clin Vaccine Immunol: CVI 17 (2010), 1086–1093.
33. Papa, A., Bino, S., Velo, E., Harxhi, A., Kota, M., Antoniadis, A., Cytokine levels in Crimean-Congo hemorrhagic fever. J Clin Virol: Off Publ Pan Am Soc Clin Virol 36 (2006), 272–276.
34. Papa, A., Tsergouli, K., Caglayik, D.Y., Bino, S., Como, N., Uyar, Y., et al. Cytokines as biomarkers of Crimean-Congo hemorrhagic fever. J Med Virol 88 (2016), 21–27.
35. Connolly-Andersen, A.M., Douagi, I., Kraus, A.A., Mirazimi, A., Crimean Congo hemorrhagic fever virus infects human monocyte-derived dendritic cells. Virology 390 (2009), 157–162.
36. Peyrefitte, C.N., Perret, M., Garcia, S., Rodrigues, R., Bagnaud, A., Lacote, S., et al. Differential activation profiles of Crimean-Congo hemorrhagic fever virus- and Dugbe virus-infected antigen-presenting cells. The J Gen Virol 91 (2010), 189–198.
37. Cevik, M.A., Erbay, A., Bodur, H., Eren, S.S., Akinci, E., Sener, K., et al. Viral load as a predictor of outcome in Crimean-Congo hemorrhagic fever. Clin Infect Dis: Off Publ Infect Dis Soc Am 45 (2007), e96–e100.
38. Duh, D., Saksida, A., Petrovec, M., Ahmeti, S., Dedushaj, I., Panning, M., et al. Viral load as predictor of Crimean-Congo hemorrhagic fever outcome. Emerg Infect Dis 13 (2007), 1769–1772.
39. Papa, A., Drosten, C., Bino, S., Papadimitriou, E., Panning, M., Velo, E., et al. Viral load and Crimean-Congo hemorrhagic fever. Emerg Infect Dis 13 (2007), 805–806.
40. Papa, A., Dalla, V., Papadimitriou, E., Kartalis, G.N., Antoniadis, A., Emergence of Crimean-Congo haemorrhagic fever in Greece. Clin Microbiol Infect: Off Publ Eur Soc Clin Microbiol Infect Dis 16 (2010), 843–847.
41. Ergunay, K., Kocak Tufan, Z., Bulut, C., Kinikli, S., Demiroz, A.P., Ozkul, A., Antibody responses and viral load in patients with Crimean-Congo hemorrhagic fever: a comprehensive analysis during the early stages of the infection. Diagn Microbiol Infect Dis 79 (2014), 31–36.
42. Kaya, A., Engin, A., Guven, A.S., Icagasioglu, F.D., Cevit, O., Elaldi, N., et al. Crimean-Congo hemorrhagic fever disease due to tick bite with very long incubation periods. Int J Infect Dis: IJID: Off Publ Int Soc Infect Dis 15 (2011), e449–e452.
43. Papa, A., Yagci Caglayik, D., Christova, I., Tsergouli, K., Korukluoglu, G., Uyar, Y., Crimean-Congo hemorrhagic fever: CXCL10 correlates with the viral load. J Med Virol 87 (2015), 899–903.
44. Yilmaz, M., Aydin, K., Akdogan, E., Sucu, N., Sonmez, M., Omay, S.B., et al. Peripheral blood natural killer cells in Crimean-Congo hemorrhagic fever. J Clin Virol: Off Publ Pan Am Soc Clin Virol 42 (2008), 415–417.
45. Akinci, E., Yilmaz, M., Bodur, H., Onguru, P., Bayazit, F.N., Erbay, A., et al. Analysis of lymphocyte subgroups in Crimean-Congo hemorrhagic fever. Int J Infect Dis: IJID: Off Publ Int Soc Infect Dis 13 (2009), 560–563.
46. Bente, D.A., Alimonti, J.B., Shieh, W.J., Camus, G., Stroher, U., Zaki, S., et al. Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. J Virol 84 (2010), 11089–11100.
47. Bereczky, S., Lindegren, G., Karlberg, H., Akerstrom, S., Klingstrom, J., Mirazimi, A., Crimean-Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor-knockout mice. J Gen Virol 91 (2010), 1473–1477.
48. Simon, M., Falk, K.I., Lundkvist, A., Mirazimi, A., Exogenous nitric oxide inhibits Crimean Congo hemorrhagic fever virus. Virus Res 120 (2006), 184–190.
49. Smirnova, S.E., Zubri, G.L., Savinov, A.P., Chumakov, M.P., Pathogenesis of experimental Crimean hemorrhagic fever infection in newborn white mice. Acta Virol 17 (1973), 409–415.
50. Gonzalez, J.P., Wilson, M.L., Cornet, J.P., Camicas, J.L., Host-passage-induced phenotypic changes in crimean-congo haemorrhagic fever virus. Res Virol 146 (1995), 131–140.
51. Akira, S., Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells 17 (1999), 138–146.
52. Butenko AM, Chumakov MP, Smirnova SE, Vasilenko SM, Zavodova TI, Tkachenko EA, et al. Isolation of Crimean hemorrhagic fever virus from blood of patients and corpse material (from 1968–1969 investigation data) in Orstov, Astrakhan Oblast, and Bulgaria. Mater 3 Oblast Nauchn Prakt Konf (Rostov-on-Don, May 1970); 1970. p. 6–25. [Russian, translated NAMRU-3 T522].
53. Fagbami, A.H., Tomori, O., Fabiyi, A., Isoun, T.T., Experimantal Congo virus (Ib-AN 7620) infection in primates. Virologie 26 (1975), 33–37.
54. Garcia-Sastre A. Diversity, replication, pathogenicity and cell biology of Crimean Congo hemorrhagic fever virus. 2010.
55. Yilmaz, R., Kundak, A.A., Ozer, S., Esmeray, H., Successful treatment of severe Crimean-Congo hemorrhagic fever with supportive measures without ribavirin and hypothermia. J Clin Virol: Off Publ Pan Am Soc Clin Virol 44 (2009), 181–182.
56. Watts, D.M., Ussery, M.A., Nash, D., Peters, C.J., Inhibition of Crimean-Congo hemorrhagic fever viral infectivity yields in vitro by ribavirin. The Am J Trop Med Hyg 41 (1989), 581–585.
57. Mardani, M., Jahromi, M.K., Naieni, K.H., Zeinali, M., The efficacy of oral ribavirin in the treatment of crimean-congo hemorrhagic fever in Iran. Clin Infect Dis: Off Publ Infect Dis Soc Am 36 (2003), 1613–1618.
58. Maltezou, H.C., Papa, A., Crimean-Congo hemorrhagic fever: epidemiological trends and controversies in treatment. BMC Med, 9, 2011, 131.
59. Koksal, I., Yilmaz, G., Aksoy, F., Aydin, H., Yavuz, I., Iskender, S., et al. The efficacy of ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Eastern Black Sea region in Turkey. J Clin Virol: Off Publ Pan Am Soc Clin Virol 47 (2010), 65–68.
60. Papa, A., Papadimitriou, E., Christova, I., The Bulgarian vaccine Crimean-Congo haemorrhagic fever virus strain. Scandinavian J Infect Dis 43 (2011), 225–229.
61. Christova, I., Kovacheva, O., Greorgieva, G., Ivanova, S., Argirov, D., Vaccine against Congo-Crimean haemorhagic fever virus-Bulgarian input in fighting the disease. Probl Infect Parasit Dis 37 (2010), 7–8.
62. Papa, A., Pappa, S., Panayotova, E., Papadopoulou, E., Christova, I., Molecular epidemiology of Crimean-Congo hemorrhagic fever in Bulgaria–An update. J Med Virol 88 (2016), 769–773.
63. Keshtkar-Jahromi, M., Kuhn, J.H., Christova, I., Bradfute, S.B., Jahrling, P.B., Bavari, S., Crimean-Congo hemorrhagic fever: current and future prospects of vaccines and therapies. Antivir Res 90 (2011), 85–92.
64. Mousavi-Jazi, M., Karlberg, H., Papa, A., Christova, I., Mirazimi, A., Healthy individuals' immune response to the Bulgarian Crimean-Congo hemorrhagic fever virus vaccine. Vaccine 30 (2012), 6225–6229.
65. Hemachudha, T., Griffin, D.E., Giffels, J.J., Johnson, R.T., Moser, A.B., Phanuphak, P., Myelin basic protein as an encephalitogen in encephalomyelitis and polyneuritis following rabies vaccination. The New England J Med 316 (1987), 369–374.
66. Hewson, R., Chamberlain, J., Mioulet, V., Lloyd, G., Jamil, B., Hasan, R., et al. Crimean-Congo haemorrhagic fever virus: sequence analysis of the small RNA segments from a collection of viruses world wide. Virus Res 102 (2004), 185–189.
67. Carter, S.D., Surtees, R., Walter, C.T., Ariza, A., Bergeron, E., Nichol, S.T., et al. Structure, function, and evolution of the Crimean-Congo hemorrhagic fever virus nucleocapsid protein. J Virol 86 (2012), 10914–10923.
68. Schmaljohn, C.S., Nichol, S.T., Bunyaviridae. Knipe, D.M., Howley, P.M., (eds.) Fields virology, 2007, Williams & Wilkins, Philadelphia, 1741–1789.
69. Maes, P., Clement, J., Van Ranst, M., Recent approaches in hantavirus vaccine development. Expert Rev Vaccines 8 (2009), 67–76.
70. Boshra, H., Lorenzo, G., Rodriguez, F., Brun, A., A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR(-/-) mice upon lethal virus challenge. Vaccine 29 (2011), 4469–4475.
71. Srinivasan, P., Kumar, S.P., Karthikeyan, M., Jeyakanthan, J., Jasrai, Y.T., Pandya, H.A., et al. Epitope-based immunoinformatics and molecular docking studies of nucleocapsid protein and ovarian tumor domain of crimean-congo hemorrhagic Fever virus. Fron Genet, 2, 2011, 72.
72. Sanchez, A.J., Vincent, M.J., Nichol, S.T., Characterization of the glycoproteins of Crimean-Congo hemorrhagic fever virus. J Virol 76 (2002), 7263–7275.
73. Altamura, L.A., Bertolotti-Ciarlet, A., Teigler, J., Paragas, J., Schmaljohn, C.S., Doms, R.W., Identification of a novel C-terminal cleavage of Crimean-Congo hemorrhagic fever virus PreGN that leads to generation of an NSM protein. J Virol 81 (2007), 6632–6642.
74. Vincent, M.J., Sanchez, A.J., Erickson, B.R., Basak, A., Chretien, M., Seidah, N.G., et al. Crimean-Congo hemorrhagic fever virus glycoprotein proteolytic processing by subtilase SKI-1. J Virol 77 (2003), 8640–8649.
75. Sanchez, A.J., Vincent, M.J., Erickson, B.R., Nichol, S.T., Crimean-congo hemorrhagic fever virus glycoprotein precursor is cleaved by Furin-like and SKI-1 proteases to generate a novel 38-kilodalton glycoprotein. J Virol 80 (2006), 514–525.
76. Haferkamp, S., Fernando, L., Schwarz, T.F., Feldmann, H., Flick, R., Intracellular localization of Crimean-Congo Hemorrhagic Fever (CCHF) virus glycoproteins. Virol J, 2, 2005, 42.
77. Bertolotti-Ciarlet, A., Smith, J., Strecker, K., Paragas, J., Altamura, L.A., McFalls, J.M., et al. Cellular localization and antigenic characterization of crimean-congo hemorrhagic fever virus glycoproteins. J Virol 79 (2005), 6152–6161.
78. Ahmed, A.A., McFalls, J.M., Hoffmann, C., Filone, C.M., Stewart, S.M., Paragas, J., et al. Presence of broadly reactive and group-specific neutralizing epitopes on newly described isolates of Crimean-Congo hemorrhagic fever virus. J Gen Virol 86 (2005), 3327–3336.
79. Ghiasi, S.M., Salmanian, A.H., Chinikar, S., Zakeri, S., Mice orally immunized with a transgenic plant expressing the glycoprotein of Crimean-Congo hemorrhagic fever virus. Clin Vaccine Immunol: CVI 18 (2011), 2031–2037.
80. Casals, J., Tignor, G.H., Neutralization and hemagglutination-inhibition tests with Crimean hemorrhagic fever-Congo virus. Proc Soc Exp Biol Med Soc Exp Biol Med 145 (1974), 960–966.
81. Conlan, A.J., Brooks Pollock, E., McKinley, T.J., Mitchell, A.P., Jones, G.J., Vordermeier, M., et al. Potential benefits of cattle vaccination as a supplementary control for bovine tuberculosis. PLoS Comput Biol, 11, 2015, e1004038.
82. Hasan, N.H., Ignjatovic, J., Peaston, A., Hemmatzadeh, F., Avian influenza virus and DIVA strategies. Viral Immunol 29 (2016), 198–211.
83. Barnett, P.V., Geale, D.W., Clarke, G., Davis, J., Kasari, T.R., A review of OIE country status recovery using vaccinate-to-live versus vaccinate-to-die foot-and-mouth disease response policies i: benefits of higher potency vaccines and associated NSP DIVA test systems in post-outbreak surveillance. Transbound Emerg Dis 62 (2015), 367–387.
84. Dowall, S.D., Richards, K.S., Graham, V.A., Chamberlain, J., Hewson, R., Development of an indirect ELISA method for the parallel measurement of IgG and IgM antibodies against Crimean-Congo haemorrhagic fever (CCHF) virus using recombinant nucleoprotein as antigen. J Virol Methods 179 (2012), 335–341.
85. Marriott, A.C., Polyzoni, T., Antoniadis, A., Nuttall, P.A., Detection of human antibodies to Crimean-Congo haemorrhagic fever virus using expressed viral nucleocapsid protein. J Gen Virol 75:Pt 9 (1994), 2157–2161.
86. Saijo, M., Tang, Q., Shimayi, B., Han, L., Zhang, Y., Asiguma, M., et al. Recombinant nucleoprotein-based serological diagnosis of Crimean-Congo hemorrhagic fever virus infections. J Med Virol 75 (2005), 295–299.
87. Magurano, F., Nicoletti, L., Humoral response in Toscana virus acute neurologic disease investigated by viral-protein-specific immunoassays. Clin Diagn Lab Immunol 6 (1999), 55–60.
88. Schwarz, T.F., Gilch, S., Pauli, C., Jager, G., Immunoblot detection of antibodies to Toscana virus. J Med Virol 49 (1996), 83–86.
89. Vapalahti, O., Kallio-Kokko, H., Narvanen, A., Julkunen, I., Lundkvist, A., Plyusnin, A., et al. Human B-cell epitopes of Puumala virus nucleocapsid protein, the major antigen in early serological response. J Med Virol 46 (1995), 293–303.
90. Shepherd, A.J., Swanepoel, R., Leman, P.A., Antibody response in Crimean-Congo hemorrhagic fever. Rev Infect Dis 11:Suppl 4 (1989), S801–S806.
91. Hinkula, J., Devignot, S., Akerstrom, S., Karlberg, H., Wattrang, E., Bereczky, S., et al. Immunization with DNA plasmids coding for crimean-congo hemorrhagic fever virus capsid and envelope proteins and/or virus-like particles induces protection and survival in challenged mice. J Virol, 2017.
92. Kortekaas, J., Vloet, R.P., McAuley, A.J., Shen, X., Bosch, B.J., de Vries, L., et al. Crimean-Congo hemorrhagic fever virus subunit vaccines induce high levels of neutralizing antibodies but no protection in STAT1 knockout mice. Vector Borne Zoonotic Dis 15 (2015), 759–764.
93. Andersson, I., Lundkvist, A., Haller, O., Mirazimi, A., Type I interferon inhibits Crimean-Congo hemorrhagic fever virus in human target cells. J Med Virol 78 (2006), 216–222.
94. Bowick, G.C., Airo, A.M., Bente, D.A., Expression of interferon-induced antiviral genes is delayed in a STAT1 knockout mouse model of Crimean-Congo hemorrhagic fever. Virol J, 9, 2012, 122.
95. Vannie, P., Capua, I., Le Potier, M.F., Mackay, D.K., Muylkens, B., Parida, S., et al. Marker vaccines and the impact of their use on diagnosis and prophylactic measures. Revue Sci Tech 26 (2007), 351–372.
96. van Oirschot, J.T., Present and future of veterinary viral vaccinology: a review. Veter Quart 23 (2001), 100–108.
97. Canakoglu, N., Berber, E., Tonbak, S., Ertek, M., Sozdutmaz, I., Aktas, M., et al. Immunization of knock-out alpha/beta interferon receptor mice against high lethal dose of Crimean-Congo hemorrhagic fever virus with a cell culture based vaccine. PLoS Neglected Trop Dis, 9, 2015, e0003579.
98. Buttigieg, K.R., Dowall, S.D., Findlay-Wilson, S., Miloszewska, A., Rayner, E., Hewson, R., et al. A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model. PloS One, 9, 2014, e91516.
99. Dowall, S.D., Buttigieg, K.R., Findlay-Wilson, S.J., Rayner, E., Pearson, G., Miloszewska, A., et al. A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease. Hum Vaccines Immunother 12 (2016), 519–527.
100. Spik, K., Shurtleff, A., McElroy, A.K., Guttieri, M.C., Hooper, J.W., SchmalJohn, C., Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine 24 (2006), 4657–4666.
101. Sahib, M.M., Rapid development of optimized recombinant adenoviral vaccines biosafety level 4 viruses: University of Manitoba. 2010, Winnipeg, Canada.
102. Ergonul, O., Crimean-Congo haemorrhagic fever. Lancet Infect Dis 6 (2006), 203–214.
103. Gunes, T., Engin, A., Poyraz, O., Elaldi, N., Kaya, S., Dokmetas, I., et al. Crimean-Congo hemorrhagic fever virus in high-risk population, Turkey. Emerging Infect Dis. 15 (2009), 461–464.
104. Smith, G.L., Moss, B., Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. Gene 25 (1983), 21–28.
105. Moss, B., Carroll, M.W., Wyatt, L.S., Bennink, J.R., Hirsch, V.M., Goldstein, S., et al. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol 397 (1996), 7–13.
106. Cottingham, M.G., Carroll, M.W., Recombinant MVA vaccines: dispelling the myths. Vaccine 31 (2013), 4247–4251.
107. Stickl, H., Hochstein-Mintzel, V., Mayr, A., Huber, H.C., Schafer, H., Holzner, A., [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]. Deut Med Wochenschr 99 (1974), 2386–2392.
108. Alcock, R., Cottingham, M.G., Rollier, C.S., Furze, J., De Costa, S.D., Hanlon, M., et al. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci Translational Med, 2, 2010, 19ra2.
109. Draper, S.J., Heeney, J.L., Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 8 (2010), 62–73.
110. Sutter, G., Wyatt, L.S., Foley, P.L., Bennink, J.R., Moss, B., A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12 (1994), 1032–1040.
111. Dowall, S.D., Graham, V.A., Rayner, E., Hunter, L., Watson, R., Taylor, I., et al. Protective effects of a Modified Vaccinia Ankara-based vaccine candidate against Crimean-Congo Haemorrhagic Fever virus require both cellular and humoral responses. PloS One, 11, 2016, e0156637.
112. Farina, S.F., Gao, G.P., Xiang, Z.Q., Rux, J.J., Burnett, R.M., Alvira, M.R., et al. Replication-defective vector based on a chimpanzee adenovirus. J Virol 75 (2001), 11603–11613.
113. Vogels, R., Zuijdgeest, D., van Rijnsoever, R., Hartkoorn, E., Damen, I., de Bethune, M.P., et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77 (2003), 8263–8271.
114. Capone, S., D'Alise, A.M., Ammendola, V., Colloca, S., Cortese, R., Nicosia, A., et al. Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Exp Rev Vaccines 12 (2013), 379–393.
115. Dudareva, M., Andrews, L., Gilbert, S.C., Bejon, P., Marsh, K., Mwacharo, J., et al. Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 27 (2009), 3501–3504.
116. Ersching, J., Hernandez, M.I., Cezarotto, F.S., Ferreira, J.D., Martins, A.B., Switzer, W.M., et al. Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys. Virology 407 (2010), 1–6.
117. Xiang, Z., Li, Y., Cun, A., Yang, W., Ellenberg, S., Switzer, W.M., et al. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis 12 (2006), 1596–1599.
118. Harrison, R.L., Jarvis, D.L., Protein N-glycosylation in the baculovirus-insect cell expression system and engineering of insect cells to produce “mammalianized” recombinant glycoproteins. Adv Virus Res 68 (2006), 159–191.
119. Devignot, S., Bergeron, E., Nichol, S., Mirazimi, A., Weber, F., A virus-like particle system identifies the endonuclease domain of Crimean-Congo hemorrhagic fever virus. J Virol 89 (2015), 5957–5967.
120. Hewson, R., Gmyl, A., Gmyl, L., Smirnova, S.E., Karganova, G., Jamil, B., et al. Evidence of segment reassortment in Crimean-Congo haemorrhagic fever virus. J Gen Virol 85 (2004), 3059–3070.
121. Oany, A.R., Ahmad, S.A., Hossain, M.U., Jyoti, T.P., Identification of highly conserved regions in L-segment of Crimean-Congo hemorrhagic fever virus and immunoinformatic prediction about potential novel vaccine. Adv Appl Bioinfor Chem: AABC 8 (2015), 1–10.
122. Tipu, H.N., Immunoinformatic analysis of crimean congo hemorrhagic fever virus glycoproteins and epitope prediction for synthetic peptide vaccine. J Coll Phys Surg–Pakistan: JCPSP 26 (2016), 108–112.
123. van Kasteren, P.B., Bailey-Elkin, B.A., James, T.W., Ninaber, D.K., Beugeling, C., Khajehpour, M., et al. Deubiquitinase function of arterivirus papain-like protease 2 suppresses the innate immune response in infected host cells. Proc Nat Acad Sci USA 110 (2013), E838–E847.
124. Bergeron, E., Albarino, C.G., Khristova, M.L., Nichol, S.T., Crimean-Congo hemorrhagic fever virus-encoded ovarian tumor protease activity is dispensable for virus RNA polymerase function. J Virol 84 (2010), 216–226.
125. Brehm, M.A., Shultz, L.D., Greiner, D.L., Humanized mouse models to study human diseases. Curr Opin Endocrinol Diabetes Obes 17 (2010), 120–125.
126. Snoy, P.J., Establishing efficacy of human products using animals: the US food and drug administration's “animal rule”. Veter Pathol 47 (2010), 774–778.
127. Papa, A., Mirazimi, A., Koksal, I., Estrada-Pena, A., Feldmann, H., Recent advances in research on Crimean-Congo hemorrhagic fever. J Clin Virol: Off Publ Pan Am Soc Clin Virol 64 (2015), 137–143.